In a 67‑year‑old male with diabetes, hypertension, Parkinson’s disease, chronic liver disease with portal hypertension, presenting with a 10‑day dry cough, exertional dyspnea, pedal edema, metabolic acidosis and hyperkalaemia while on metformin, telmisartan and carbidopa/levodopa, what medication adjustments and acute management steps should be taken?

Immediate Medication Management in Acute Illness with Metabolic Acidosis

Stop metformin immediately and do not restart until the patient is stable, eating normally, and has documented normal renal function—this is metformin-associated lactic acidosis (MALA) in the setting of chronic liver disease and acute illness. 1

Critical Medication Discontinuations

Metformin - STOP NOW

• Metformin is absolutely contraindicated in this patient with multiple risk factors for lactic acidosis: chronic liver disease (impaired lactate clearance), acute illness with volume depletion, and compensated metabolic acidosis with pH 7.315 1
• The FDA label explicitly states metformin should be avoided in patients with hepatic disease due to impaired lactate clearance 1
• Consensus sick day guidance recommends stopping metformin during acute illness with vomiting, diarrhea, or decreased fluid intake for up to 3 days or until symptoms resolve 2
• The Lancet guideline emphasizes metformin should be discontinued in patients at risk for lactic acidosis including those with liver failure, hypoxia, or acute illness 3
• Do not restart until: patient eating/drinking normally for 24-48 hours, renal function confirmed stable, and liver function reassessed 2, 1

Telmisartan - STOP NOW

• Discontinue telmisartan immediately due to recurrent hyperkalemia (current K+ 5.3, previous 5.8) 2
• ARBs should be temporarily stopped during acute illness with volume depletion, as recommended by sick day guidance for patients with symptoms like decreased fluid intake and pedal edema 2
• The FDA label warns of hyperkalemia risk, particularly relevant in this patient with chronic liver disease and potential renal impairment 4
• Resume only after 24-48 hours of normal eating/drinking and documented normalization of potassium 2

NSAIDs - Confirm Discontinuation

• If any NSAIDs are among the 12 neurologic medications, ensure they are stopped given his 6-month history of NSAID use for post-chikungunya arthritis 2
• NSAIDs should be temporarily stopped during acute illness per sick day guidance 2

Acute Respiratory Management

Bronchospasm Treatment

• Administer hydrocortisone 100 mg IV stat as planned for bronchospasm with continuous cough 3
• Consider bronchodilator therapy (albuterol nebulizer) for decreased breath sounds bilaterally 3

Volume Status Assessment

• The patient has conflicting signs: pedal edema suggesting volume overload BUT metabolic acidosis and sick day presentation suggesting volume depletion 2
• BP 160/80 mmHg is elevated, possibly from stopping antihypertensive or underlying hypertensive heart disease 2
• Do NOT give aggressive IV fluids given pulmonary hypertension and heart failure on echo—risk of pulmonary edema 3
• Monitor closely for signs of worsening heart failure (orthopnea, PND, oxygen desaturation) 3

Diabetes Management During Acute Illness

Immediate Glucose Control

• Continue carbidopa/levodopa as prescribed—do not interrupt Parkinson's medications during acute illness 5, 6
• Transition to basal-bolus insulin regimen now that metformin is stopped 3
• Start with basal insulin (e.g., glargine 10 units daily) and correctional rapid-acting insulin for glucose >180 mg/dL 3
• Monitor blood glucose every 4-6 hours during acute illness 2
• Target glucose <180 mg/dL (10 mmol/L) in hospitalized patients 3

Long-term Diabetes Management Post-Discharge

• Do NOT restart metformin in this patient with documented chronic liver disease with portal hypertension—metformin is contraindicated 1, 7
• Consider GLP-1 receptor agonist (e.g., liraglutide, semaglutide) as these have renal rather than hepatic excretion and are safer in liver disease 3, 7
• Avoid sulfonylureas due to hypoglycemia risk in elderly patients with multiple comorbidities 3
• DPP-4 inhibitors (e.g., sitagliptin, linagliptin) show only mild PK changes in hepatic impairment and may be considered 7

Hypertension Management

Acute Phase

• Monitor BP closely after stopping telmisartan—expect some elevation 4
• If BP remains >160/100 mmHg after acute illness resolves, consider alternative antihypertensive 4

Long-term Management

• Switch from ARB to calcium channel blocker (e.g., amlodipine) which does not cause hyperkalemia and is safer in chronic liver disease 2
• Alternatively, consider low-dose thiazide if renal function permits, though this should be stopped during future sick days 2
• Avoid restarting telmisartan given recurrent hyperkalemia 4

Monitoring During Acute Illness

Laboratory Monitoring

• Recheck VBG in 6-12 hours to ensure acidosis is improving after stopping metformin 1
• Monitor potassium daily until normalized (<5.0 mEq/L) 2, 4
• Check lactate level to confirm lactic acidosis component of metabolic acidosis 1
• Monitor renal function (creatinine, eGFR) daily during acute illness 1
• If lactate >5 mmol/L or acidosis worsens, consider hemodialysis (metformin is dialyzable) 1

Clinical Monitoring

• Assess volume status carefully: jugular venous pressure, lung auscultation, daily weights 3
• Monitor for signs of worsening heart failure given pulmonary hypertension 3
• Continue monitoring oxygen saturation 3

Chronic Liver Disease Evaluation

Etiology Investigation

• The patient has chronic liver disease with portal hypertension but negative NASH workup and no alcohol history 8
• Consider drug-induced liver injury given 6-month NSAID use and multiple medications (12 neurologic drugs) 7
• Evaluate for hemochromatosis (occupational exposure to heavy equipment, history of anemia requiring transfusion) 8
• Check hepatitis B and C serologies if not already done 8
• Consider autoimmune hepatitis workup (ANA, ASMA, immunoglobulins) 8
• Wilson disease is unlikely at age 67 but consider if other causes excluded 8
• Cardiac cirrhosis from long-standing hypertensive heart disease and pulmonary hypertension is possible 8

Liver-Specific Medication Considerations

• Avoid hepatotoxic medications going forward 7
• Many Parkinson's medications are hepatically metabolized—review all 12 medications when records arrive 7
• Consider dose adjustments for hepatically cleared drugs in cirrhosis 7

Critical Pitfalls to Avoid

• Never restart metformin in chronic liver disease—this is an absolute contraindication regardless of glucose control 1, 7
• Do not aggressively fluid resuscitate without assessing heart failure status—this patient has pulmonary hypertension 3
• Do not restart telmisartan without addressing hyperkalemia and considering alternative agents 2, 4
• Do not assume all pedal edema is from heart failure—consider hepatic etiology (hypoalbuminemia from cirrhosis) 8
• Ensure all 12 neurologic medications are reviewed for hepatotoxicity and drug interactions when records arrive 7
• Do not stop carbidopa/levodopa during acute illness—Parkinson's medications should be continued 5, 6